双时相门冬胰岛素30联合艾塞那肽对血糖控制不佳2型糖尿病的疗效及安全性分析

目的:探讨双时相门冬胰岛素30联合艾塞那肽在口服降糖药物和基础胰岛素血糖控制不佳的2型糖尿病的疗效及安全性。方法:将在我院接受治疗的72例既往使用的口服降糖药联合基础胰岛素治疗血糖控制不佳的2型糖尿病患者随机、平行、开放平分成治疗组(BIAsp30+艾塞那肽治疗,早餐和晚餐前注射BIAsp30和艾塞那肽注射液)和对照组(睡前1次皮下注射甘精胰岛素),两组均与二甲双胍联合用药。比较两组治疗前后8点血糖谱;比较两组日胰岛素用量、BMI、HbA1c以及低血糖发生次数;比较两组不良事件。结果:治疗8周、16周后,两组8个点血糖与治疗前相比均有明显下降,差异有显著性(P0.05);治疗8周后、16周后,治疗组早餐前和早餐后2小时血糖、午餐前和午餐后2小时血糖值分别与对照组的血糖相比,有统计学差异(P0.05);两组之间的晚餐前和晚餐后2小时血糖、睡觉前血糖(晚上10点)和凌晨3点血糖相互比较无显著性差异(P0.05);治疗16周后,每天胰岛素类似物用量、BMI组间比较无统计学意义(P0.05);两组治疗后HbA1c分别与治疗前相比有统计学意义(P0.05),治疗组治疗后HbA1c与对照组治疗后HbA1c相比,差异有显著性(P0.05);两组低血糖发生次数有明显差异(P0.05);两组不良事件次数相互比较无统计学意义(P0.05)。结论:BIAsp30联合艾塞那肽可显著改善基础胰岛素联合OAD血糖控制不佳的2型糖尿病患者的血糖控制,有效控制血糖,并具有良好的安全性。

Analysis of the Efficacy and Safety of the Biphasic Insulin Aspart 30 Combined with Exenatide Treating Patients with Type 2 Diabetes Inadequately Controlled on Human Insulin

Objective:To explore the efficacy and safety the biphasic insulin aspart 30 (BIAsp30) combined with exenatide Glargine patients with type 2 diabetes patients switching from basal integrated with oral anti-diabetic drugs.Methods:76 patients with T2DMinadequately controlled on basal insulin with oral anti-diabetic drugs were divided randomly, openly, parallel into two groups, the treating group (n=36) was treated BIAsp30 combined with exenatidel; while the control group was treated with (n=36) glargine. Both of the two groups were accepted with Metformin. Comparing the glucose spectrum of 8 time points, the dosage of insulin analogs, BMI, HbA1c, overall hypoglycemia and the adverse events between two groups.Results:After 8 weeks and 16 weeks'' treatment, the blood glucose of 8 time points at the two groups decreased, which was statistical to compare that before treatment at the same group(P<0.05); Besides, the glucose before breakfast, glucose after breakfast, glucose before lunch, glucose after lunch in the treating groups was statistical less than that in the control group (P<0.05); However, there was no statistical meaning to compare the remaining glucose of 4 time points at the two groups (P>0.05); After 16 weeks'' treatment, there was no statistical difference of the dosage of insulin analogs, BMI between two group (P>0.05); and it was statistical to compare the HbA1c in the treating group than that in the control group (P<0.05); the HbA1c after treatment in the treating group was less that that after treatment in the control group (P<0.05); there was no statistical difference of the overall hypoglycemia and the adverse events between two groups(P>0.05).